[1]
|
G. M. Keating, “Rituximab: A Review of Its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma,” Drugs, Vol. 70, No. 11, 2010, pp. 1445-1476.
http://dx.doi.org/10.2165/11201110-000000000-00000
|
[2]
|
F. Hagemeister, “Rituximab for the Treatment of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukaemia,” Drugs, Vol. 70, No. 3, 2010, pp. 261-272.
http://dx.doi.org/10.2165/11532180-00000 0000-00000
|
[3]
|
R. Marcus, K. Imrie, P. Solal-Celigny, J. V. Catalano, A. Dmoszynska, J. C. Raposo, F. C. Offner, J. Gomez-Codina, A. Belch , D. Cunningham , E. Wassner-Fritsch and G. Stein, “Phase III Study of R-CVP Compared with Cyclophosphamide, Vincristine, and Prednisone Alone in Patients with Previously Untreated Advanced Follicular Lymphoma,” Journal of Clinical Oncology, Vol. 26, No. 28, 2008, pp. 4579-4586.
http://dx.doi.org/10.1200/JCO.2007.13.5376
|
[4]
|
M. Herold, A. Haas, S. Srock, S. Neser, K. H. Al-Ali, A. Neubauer, G. Dolken, R. Naumann, W. Knauf, M. Freund, R.Rohrberg, K. Hoffken, A. Franke, T. Ittel, E. Kettner, U. Haak, U. Mey, C. Klinkenstein, M. Assmann, U. von Grünhagen, East German Study Group Hematology and Oncology Study, “Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients with Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study,” Journal of Clinical Oncology, Vol. 25, No. 15, 2007, pp. 1986-1992. http://dx.doi.org/10.1200/JCO.2006.06.4618
|
[5]
|
M. Pfreundschuh, L. Trümper, A. Osterborg, R. Pettengell, M. Trneny, K. Imrie, D. Ma, D. Gill, J. Walewski, P. L. Zinzani, R. Stahel, S. Kvaloy, O. Shpilberg, U. Jaeger, M. Hansen, T. Lehtinen, A. López-Guillermo , C. Corrado, A. Scheliga, N. Milpied, M. Mendila, M. Rashford, E. Kuhnt, M. Loeffler, MabThera International Trial Group, “CHOP-Like Chemotherapy plus Rituximab versus CHOP-Like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma: A Randomised Controlled Trial by the MabThera International Trial (MInT) Group,” Lancet Oncology, Vol. 7, No. 5, 2006, pp. 379-391.
http://dx.doi.org/10.1016/S1470-2045(06)70664-7
|
[6]
|
B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, F. Reyes, P. Lederlin and C. Gisselbrecht, “CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma,” New England Journal of Medicine, Vol. 346, No. 4, 2002, pp. 235-242.
http://dx.doi.org/10.1056/NEJMoa011795
|
[7]
|
M. Hallek, K. Fischer, G. Fingerle-Rowson, A. M. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, M. Bergmann, J. Catalano, P. L. Zinzani, F. Caligaris-Cappio, J. F. Seymour, A. Berrebi, U. Jager, B. Cazin, M. Trneny, A. Westermann, C. M. Wendtner, B. F. Eichhorst, P. Staib, A. Bühler, D. Winkler, T. Zenz, S. Bottcher, M. Ritgen, M. Mendila, M. Kneba, H. Dohner, S. Stilgenbauer, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group, “Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukaemia: A Randomised, Open-Label, Phase 3 Trial,” Lancet, Vol. 376, No 9747, 2010, pp. 1164-1174.
http://dx.doi.org/10.1016/S0140-6736(10)61381-5
|
[8]
|
Avalere Health, LLC, “Total Cost of Cancer Care by Site of Service: Physician Office vs Outpatient Hospital,” 2012. http://www.avalerehealth.net/news/2012-04-03_COA/Cost_of_Care.pdf
|
[9]
|
K. Fitch, B. Pyenson, Milliman Inc., “Siteof Service Cost Differences for Medicare Patients Receiving Chemotherapy,” 2011.
http://publications.milliman.com/publications/health-published/pdfs/site-of-service-cost-differences.pdf
|
[10]
|
H. Quan, V. Sundararajan, P. Halfon, A. Fong, B. Burnand, J. C. Luthi, L. D. Saunders, C. A. Beck, T. E. Feasby and W. A. Ghali, “Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data,” Medical Care, Vol. 43, No. 11, 2005, pp. 1130-1139.
http://dx.doi.org/10.1097/01.mlr.0000182534.19832.83
|
[11]
|
Genentech, “Rituxan Package Insert,” 2013.
http://www.gene.com/download/pdf/rituxan_prescri bing.pdf
|
[12]
|
The Medicare Payment Advisory Commission (MedPAC), “Report to the Congress: Medicare Payment Policy,” 2012. http://medpac.gov/chapters/Mar12_Ch03.pdf
|
[13]
|
T. U. Guidi, “Medicare’s Hospital Outpatient Prospective Payment System: OPPS 101,” Journal of Oncology Practice, Vol. 6, No. 6, 2010, pp. 321-324.
http://dx.doi.org/10.1200/JOP.2010.000163
|
[14]
|
B. O. Wynn, P. S. Hussey and T. Ruder, “Policy Options for Addressing Medicare Payment Differentials Across Ambulatory Settings,” 2011.
http://www.rand.org/pubs/technical_reports/TR979.html
|
[15]
|
W. R. Robinson and J. Beyer, “Impact of Shifting from Officeto Hospital-Based Treatment Facilities on the Administration of Intraperitoneal Chemotherapy for Ovarian Cancer,” Journal of Oncology Practice, Vol. 6, No. 5, 2010, pp. 232-235. http://dx.doi.org/10.1200/JOP.000058
|
[16]
|
M. Jacobson, C. C. Earle, M. Price and J. P. Newhouse, “How Medicare’s Payment Cuts for Cancer Chemotherapy Drugs Changed Patterns of Treatment,” Health Affairs, Vol. 29, No. 7, 2010, pp. 1391-1399.
http://dx.doi.org/10.1377/hlthaff.2009.0563
|
[17]
|
R. M. Conti and P. B. Bach, “Cost Consequences of the 340B Drug Discount Program,” The Journal of the American Medical Association, Vol. 309, No. 19, 2013, pp. 1995-1996. http://dx.doi.org/10.1001/ jama.2013.4156
|
[18]
|
US Department of Health and Human Services, Office of the Inspector General, “Payment for Drugs under the Hospital Outpatient Prospective Payment System,” 2010.
http://oig.hhs.gov/oei/reports/ oei-03-09-00420.pdf
|
[19]
|
Community Oncology Alliance, “Community Oncology Practice Impact Report: The Changing Landscape of Cancer care,” 2012.
http://www.communityoncology.org/pdfs/community-oncology-practice -impact-report.pdf
|
[20]
|
J. Zoeller and P. Sonnenreich, “A Survey of Oncology Trends: The Oncologist’s Perspective,” P & T, Vol. 36, No. 12, 2011, pp. 82682-82688.
|